Reina Haque to Female
This is a "connection" page, showing publications Reina Haque has written about Female.
Connection Strength
1.103
-
Association of Physical Activity With Risk of Mortality Among Breast Cancer Survivors. JAMA Netw Open. 2022 11 01; 5(11):e2242660.
Score: 0.071
-
Sleep medication use and risk of fractures in breast cancer survivors. Breast Cancer Res Treat. 2021 Dec; 190(3):541-548.
Score: 0.066
-
Patterns of overall mortality by race/ethnicity and socioeconomic status in insured cancer patients in Southern California. Cancer Causes Control. 2021 Jun; 32(6):609-616.
Score: 0.064
-
SARS-CoV-2 Testing, Positivity Rates, and Healthcare Outcomes in a Cohort of 22,481 Breast Cancer Survivors. JCO Clin Cancer Inform. 2021 02; 5:168-175.
Score: 0.063
-
Feasibility, patient compliance and acceptability of ovarian cancer surveillance using two serum biomarkers and Risk of Ovarian Cancer Algorithm compared to standard ultrasound and CA 125 among women with BRCA mutations. Gynecol Oncol. 2020 05; 157(2):521-528.
Score: 0.059
-
Medication adherence, molecular monitoring, and clinical outcomes in patients with chronic myelogenous leukemia in a large HMO. J Am Pharm Assoc (2003). 2017 May - Jun; 57(3):303-310.e2.
Score: 0.048
-
Cardiovascular Disease After Aromatase Inhibitor Use. JAMA Oncol. 2016 Dec 01; 2(12):1590-1597.
Score: 0.047
-
Effectiveness of bisphosphonate use and risk of contralateral breast cancer and recurrence in women with early-stage breast cancer treated with tamoxifen. Breast Cancer Res Treat. 2016 Apr; 156(2):379-89.
Score: 0.045
-
Tamoxifen and Antidepressant Drug Interaction in a Cohort of 16,887 Breast Cancer Survivors. J Natl Cancer Inst. 2016 Mar; 108(3).
Score: 0.044
-
A hybrid approach to identify subsequent breast cancer using pathology and automated health information data. Med Care. 2015 Apr; 53(4):380-5.
Score: 0.042
-
Aromatase inhibitors, tamoxifen, and endometrial cancer in breast cancer survivors. Cancer. 2015 Jul 01; 121(13):2147-55.
Score: 0.042
-
Adherence to endocrine therapy in breast cancer adjuvant and prevention settings. Cancer Prev Res (Phila). 2014 Apr; 7(4):378-87.
Score: 0.039
-
Comorbidities and cardiovascular disease risk in older breast cancer survivors. Am J Manag Care. 2014; 20(1):86-92.
Score: 0.039
-
Effectiveness of aromatase inhibitors and tamoxifen in reducing subsequent breast cancer. Cancer Med. 2012 Dec; 1(3):318-27.
Score: 0.035
-
Impact of breast cancer subtypes and treatment on survival: an analysis spanning two decades. Cancer Epidemiol Biomarkers Prev. 2012 Oct; 21(10):1848-55.
Score: 0.035
-
Long-term safety of radiotherapy and breast cancer laterality in older survivors. Cancer Epidemiol Biomarkers Prev. 2011 Oct; 20(10):2120-6.
Score: 0.033
-
Treatment of ductal carcinoma in situ among patients cared for in large integrated health plans. Am J Manag Care. 2010 May; 16(5):351-60.
Score: 0.030
-
Breast cancer risk in a large cohort of female antidepressant medication users. Cancer Lett. 2005 Apr 18; 221(1):61-5.
Score: 0.021
-
The Influence of Dietary Isothiocyanates on the Effectiveness of Mitomycin C and Bacillus Calmette-Gu?rin in Treating Nonmuscle-Invasive Bladder Cancer. J Urol. 2024 Sep; 212(3):420-430.
Score: 0.020
-
Arsenic in drinking water and skin lesions: dose-response data from West Bengal, India. Epidemiology. 2003 Mar; 14(2):174-82.
Score: 0.018
-
Smoking Behaviors and Prognosis in Patients With Non-Muscle-Invasive Bladder Cancer in the Be-Well Study. JAMA Netw Open. 2022 11 01; 5(11):e2244430.
Score: 0.018
-
Accelerated mononuclear cell telomere attrition in breast cancer survivors with depression history: A 2-year longitudinal cohort study. Cancer. 2022 Aug 15; 128(16):3109-3119.
Score: 0.017
-
Development of a longitudinal two-biomarker algorithm for early detection of ovarian cancer in women with BRCA mutations. Gynecol Oncol. 2020 12; 159(3):804-810.
Score: 0.015
-
Novel tumor markers provide improved prediction of survival after diagnosis of human immunodeficiency virus (HIV)-related diffuse large B-cell lymphoma. Leuk Lymphoma. 2018 02; 59(2):321-329.
Score: 0.012
-
Discordance between original and central laboratories in ER and HER2 results in a diverse, population-based sample. Breast Cancer Res Treat. 2017 01; 161(2):375-384.
Score: 0.012
-
Continuous Combined Estrogen Plus Progestin and Endometrial Cancer: The Women's Health Initiative Randomized Trial. J Natl Cancer Inst. 2016 Mar; 108(3).
Score: 0.011
-
Benefit/risk for adjuvant breast cancer therapy with tamoxifen or aromatase inhibitor use by age, and race/ethnicity. Breast Cancer Res Treat. 2015 Dec; 154(3):609-16.
Score: 0.011
-
Stromal immune infiltration in HIV-related diffuse large B-cell lymphoma is associated with HIV disease history and patient survival. AIDS. 2015 Sep 24; 29(15):1943-51.
Score: 0.011
-
Risk Prediction for Local Breast Cancer Recurrence Among Women with DCIS Treated in a Community Practice: A Nested, Case-Control Study. Ann Surg Oncol. 2015 Dec; 22 Suppl 3:S502-8.
Score: 0.011
-
A comparative study of molecular characteristics of diffuse large B-cell lymphoma from patients with and without human immunodeficiency virus infection. Clin Cancer Res. 2015 Mar 15; 21(6):1429-37.
Score: 0.010
-
Incident comorbidities and all-cause mortality among 5-year survivors of Stage I and II breast cancer diagnosed at age 65 or older: a prospective-matched cohort study. Breast Cancer Res Treat. 2014 Jul; 146(2):401-9.
Score: 0.010
-
Fracture risk in older, long-term survivors of early-stage breast cancer. J Am Geriatr Soc. 2013 Jun; 61(6):888-95.
Score: 0.009
-
Risk factors for non-invasive and invasive local recurrence in patients with ductal carcinoma in situ. Breast Cancer Res Treat. 2013 Jun; 139(2):453-60.
Score: 0.009
-
Validation of AJCC TNM staging for breast tumors diagnosed before 2004 in cancer registries. Cancer Causes Control. 2012 Sep; 23(9):1587-91.
Score: 0.009
-
Ten-year risk of diagnostic mammograms and invasive breast procedures after breast-conserving surgery for DCIS. J Natl Cancer Inst. 2012 Apr 18; 104(8):614-21.
Score: 0.009
-
Relationship between clinical and pathologic features of ductal carcinoma in situ and patient age: an analysis of 657 patients. Am J Surg Pathol. 2009 Dec; 33(12):1802-8.
Score: 0.007
-
Declining recurrence among ductal carcinoma in situ patients treated with breast-conserving surgery in the community setting. Breast Cancer Res. 2009; 11(6):R85.
Score: 0.007
-
Breast cancer recurrence in older women five to ten years after diagnosis. Cancer Epidemiol Biomarkers Prev. 2009 Nov; 18(11):2979-83.
Score: 0.007
-
A most stubborn bias: no adjustment method fully resolves confounding by indication in observational studies. J Clin Epidemiol. 2010 Jan; 63(1):64-74.
Score: 0.007
-
Adherence to long-term surveillance mammography among women with ductal carcinoma in situ treated with breast-conserving surgery. J Clin Oncol. 2009 Jul 01; 27(19):3211-6.
Score: 0.007
-
Abstracting height and weight from medical records, and breast cancer pathologic factors. Cancer Causes Control. 2008 Dec; 19(10):1217-26.
Score: 0.007
-
Diffusion of aromatase inhibitors for breast cancer therapy between 1996 and 2003 in the Cancer Research Network. Breast Cancer Res Treat. 2008 Feb; 107(3):397-403.
Score: 0.006
-
Children's intellectual function in relation to arsenic exposure. Epidemiology. 2007 Jan; 18(1):44-51.
Score: 0.006
-
Bronchiectasis in persons with skin lesions resulting from arsenic in drinking water. Epidemiology. 2005 Nov; 16(6):760-5.
Score: 0.005
-
Decrements in lung function related to arsenic in drinking water in West Bengal, India. Am J Epidemiol. 2005 Sep 15; 162(6):533-41.
Score: 0.005
-
Nutritional factors and susceptibility to arsenic-caused skin lesions in West Bengal, India. Environ Health Perspect. 2004 Jul; 112(10):1104-9.
Score: 0.005